This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

New Data About The Safety And Efficacy Of Linagliptin In Adults With Type 2 Diabetes Who Have Moderate To Severe Renal Impairment Presented At ADA

RIDGEFIELD, Conn. and INDIANAPOLIS, June 22, 2013 /PRNewswire/ --  Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced results from a new study in which linagliptin demonstrated statistically significant reductions in blood glucose levels (HbA 1c) after 12 weeks (the study's primary endpoint) in adults with type 2 diabetes (T2D) with moderate to severe renal impairment, compared with placebo. Most patients had T2D for more than ten years (76 percent) and were on insulin (86 percent).

Over an extension period (week 12 to week 52), patients treated with linagliptin had an overall improvement in blood glucose levels that was similar to those patients who had initially received placebo for 12 weeks and were thereafter switched to glimepiride for the remaining 40 weeks. Patients treated with linagliptin had a lower rate of hypoglycemia compared to those treated with glimepiride. 1

"These findings add to the growing body of knowledge for health care providers managing the increasing number of patients with type 2 diabetes and renal impairment," said Christophe Arbet-Engels MD, PhD, vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "Special considerations should be taken when prescribing treatments for the nearly two-thirds of people living with type 2 diabetes who are at risk of declining renal function."

About the Study These new findings were derived from a double-blinded trial including 235 people with T2D and moderate to severe RI (estimated glomerular filtration rate <60 mL/min/1.73m 2). For analysis of the primary endpoint, patients were randomized to linagliptin, 5 mg once daily (n=113) or placebo (n=122) for 12 weeks. For the 40-week extension period, patients initially randomized to placebo were switched to glimepiride 1-4 mg once daily and treatment continued in both groups to week 52 (n=107, linagliptin 5 mg and n=114, glimepiride 1-4 mg). The primary endpoint was the reduction in HbA 1c levels from baseline at 12 weeks. Mean HbA 1c levels at baseline were 8.08 percent for the linagliptin group and 8.03 percent for the placebo/glimepiride group.

Key results from the study showed:

  • Greater mean reduction from baseline HbA 1c at 12 weeks for patients treated with linagliptin vs. placebo (-0.53 percent vs. -0.11 percent, respectively; treatment difference –0.42 percent, 95 percent CI -0.60, -0.24; p<0.0001)
  • In the 40-week extension, the change in mean HbA 1c was similar for linagliptin and glimepiride
  • Over the extension period, there was less hypoglycemia with linagliptin vs. glimepiride-treated patients (57.9 percent vs. 69.3 percent)

Linagliptin, which is marketed as Tradjenta® (linagliptin) tablets in the U.S., is a once-daily 5mg tablet used along with diet and exercise to improve glycemic control in adults with type 2 diabetes. Linagliptin should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis (increased ketones in the blood or urine). If you have had inflammation of the pancreas (pancreatitis) in the past, it is not known if you have a higher chance of getting pancreatitis while you take linagliptin. Linagliptin is a DPP-4 inhibitor that does not require dose adjustment, regardless of declining renal function or hepatic impairment.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs